Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.

authors

Smaill, Fiona
Brophy, Jason
Bitnun, Ari
Alimenti, Ariane
Lapointe, Normand
Samson, Lindy
Read, Stanley
Karatzios, Christos
Dobson, Simon
Moses, Erin
Blitz, Sandra
Lipsky, Nancy-Grace
Ogilvie, Gina
Walmsley, Sharon
Raboud, Janet
Money, Deborah

status

published

publication date

June 2018

has subject area

1114 Paediatrics and Reproductive Medicine (FoR)
1117 Public Health and Health Services (FoR)
Adolescent (MeSH)
Antibodies, Viral (MeSH)
CD4 Lymphocyte Count (MeSH)
Canada (MeSH)
Child (MeSH)
Female (MeSH)
HIV Infections (MeSH)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (MeSH)
Humans (MeSH)
Immunogenicity, Vaccine (MeSH)
Longitudinal Studies (MeSH)
Papillomavirus Infections (MeSH)
Pediatrics (Science Metrix)
Prospective Studies (MeSH)

published in

Pediatric Infectious Disease Journal Journal